# InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces US$175M Registered Direct Offering With Warrants Priced at US$6.51

This article has been disseminated on behalf of Cybin and may include paid advertising.

 Cybin (NYSE American: CYBN) (Cboe CA: CYBN) announced a registered direct offering of 22,277,750 common shares and, in lieu of shares for certain investors, pre-funded common share purchase warrants at US$6.51 per share or pre-funded warrant for aggregate gross proceeds of US$175,009,911.45; each share or pre-funded warrant is accompanied by 0.35 of one common share purchase warrant exercisable at US$8.14 per share until the earlier of June 30, 2027, 30 days after topline data is released for the APPROACH trial of CYB003 in major depressive disorder, or 30 days after an acceleration notice if the NYSE American closing price equals or exceeds US$19.53 for five consecutive trading days; participants include new and existing investors such as Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, Acorn Bioventures, Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Management, Stonepine Capital Management, Pivotal Bioventure Partners and Ally Bridge Group.

 To view the full press release, visit https://ibn.fm/TPxvo

 About Cybin

 Cybin(R) is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

 With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

 Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland.

 NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-cybin-inc-nyse-american-cybn-cboe-ca-cybn-announces-us175m-registered-direct-offering-with-warrants-priced-at-us6-51-2/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/cybin-raises-175m-in-direct-offering-for-mental-health-breakthroughs/6082dfdcafeede59640d131114bcb6c7) 


Pickup - [https://burstable.news/news](https://burstable.news/news/202511/272461-cybin-inc-secures-175-million-in-registered-direct-offering-to-advance-neuropsychiatry-pipeline)

Pickup - [https://estallarnoticias.com/](https://estallarnoticias.com//202511/272462-cybin-inc-anuncia-oferta-directa-registrada-de-us-175-millones-para-avanzar-tratamientos-de-salud-mental)

Pickup - [https://platzennachrichten.de/nachrichten](https://platzennachrichten.de/nachrichten/202511/272467-cybin-inc-sichert-sich-175-millionen-us-dollar-durch-registriertes-direktangebot-fur-psychiatrische-arzneimittelentwicklung)

Pickup - [https://actueclair.com](https://actueclair.com/202511/272466-cybin-inc-annonce-une-offre-directe-enregistree-de-175-millions-de-dollars-americains-pour-financer-ses-therapies-innovantes-en-sante-mentale)

Pickup - [https://cannabis.in-focus.news](https://cannabis.in-focus.news/202511/272469-cybin-secures-175-million-in-direct-offering-to-advance-psychedelic-mental-health-treatments)

Pickup - [https://faqstaq.news/news](https://faqstaq.news/news/202511/272470-faq-cybin-inc-s-us-175m-registered-direct-offering-and-corporate-overview)

Pickup - [https://themaverickpr.com/services/cannabis-news](https://themaverickpr.com/services/cannabis-news/202511/272468-cybin-secures-175-million-in-direct-offering-to-advance-psychedelic-mental-health-treatments)

Pickup - [https://goinvest.com/ibn-faqstaq](https://goinvest.com/ibn-faqstaq/202511/272471-faq-cybin-inc-s-us-175m-registered-direct-offering-and-company-overview)
 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2511/2/fernR4Qz.webp)